8HC2
SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 1 YB9-258 Fab (1 RBD up)
これはPDB形式変換不可エントリーです。
8HC2 の概要
エントリーDOI | 10.2210/pdb8hc2/pdb |
EMDBエントリー | 34649 |
分子名称 | Spike glycoprotein, Light chain of YB9-258 Fab, Heavy chain of YB9-258 Fab, ... (5 entities in total) |
機能のキーワード | spike protein, rbd, antibody, fab, viral protein, viral protein-immune system complex, viral protein/immune system |
由来する生物種 | Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2) 詳細 |
タンパク質・核酸の鎖数 | 5 |
化学式量合計 | 472142.29 |
構造登録者 | |
主引用文献 | Yu, H.,Liu, B.,Zhang, Y.,Gao, X.,Wang, Q.,Xiang, H.,Peng, X.,Xie, C.,Wang, Y.,Hu, P.,Shi, J.,Shi, Q.,Zheng, P.,Feng, C.,Tang, G.,Liu, X.,Guo, L.,Lin, X.,Li, J.,Liu, C.,Huang, Y.,Yang, N.,Chen, Q.,Li, Z.,Su, M.,Yan, Q.,Pei, R.,Chen, X.,Liu, L.,Hu, F.,Liang, D.,Ke, B.,Ke, C.,Li, F.,He, J.,Wang, M.,Chen, L.,Xiong, X.,Tang, X. Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants. Nat Commun, 14:1058-1058, 2023 Cited by PubMed Abstract: SARS-CoV-2 Omicron variants feature highly mutated spike proteins with extraordinary abilities in evading antibodies isolated earlier in the pandemic. Investigation of memory B cells from patients primarily with breakthrough infections with the Delta variant enables isolation of a number of neutralizing antibodies cross-reactive to heterologous variants of concern (VOCs) including Omicron variants (BA.1-BA.4). Structural studies identify altered complementarity determining region (CDR) amino acids and highly unusual heavy chain CDR2 insertions respectively in two representative cross-neutralizing antibodies-YB9-258 and YB13-292. These features are putatively introduced by somatic hypermutation and they are heavily involved in epitope recognition to broaden neutralization breadth. Previously, insertions/deletions were rarely reported for antiviral antibodies except for those induced by HIV-1 chronic infections. These data provide molecular mechanisms for cross-neutralization of heterologous SARS-CoV-2 variants by antibodies isolated from Delta variant infected patients with implications for future vaccination strategy. PubMed: 36828833DOI: 10.1038/s41467-023-36761-0 主引用文献が同じPDBエントリー |
実験手法 | ELECTRON MICROSCOPY (6.21 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード